Azimilide
Alternative Names: NE-10064; StedicorLatest Information Update: 18 May 2020
At a glance
- Originator Procter & Gamble
- Developer AbbVie; Blue Ash Therapeutics; Mitsubishi Tanabe Pharma Corporation; Procter & Gamble
- Class Class III antiarrhythmics; Imidazolidines; Piperazines
- Mechanism of Action Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Ventricular arrhythmias
- No development reported Arrhythmias; Atrial fibrillation; Atrial flutter; Postmyocardial infarction; Supraventricular arrhythmias
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 11 Aug 2015 Azimilide is still in phase III development for Ventricular arrhythmias in USA
- 01 Jul 2014 Forest Laboratories has been acquired by Actavis Inc